Mercury Biopharmaceutical (6932.TWO) Earnings Analysis
Mercury Biopharmaceutical (6932.TWO) has no confirmed upcoming earnings date. Trailing P/E -35.44.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 6932.TWO next report earnings?
No confirmed upcoming earnings date is currently scheduled for 6932.TWO. This page updates as the calendar is published.
6932.TWO earnings history — beats and misses
No reported earnings history is available for this symbol in our dataset.
6932.TWO valuation and analyst view
| Trailing P/E | -35.44 |
|---|---|
| Trailing EPS | -0.1591 TWD |
| Price / book | 10.91 |
| Dividend yield | 0.00% |
| Market cap | 2.37B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Mercury Biopharmaceutical (6932.TWO)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 6932.TWO. This page updates as the calendar is published.
What is 6932.TWO's current P/E ratio and EPS?
6932.TWO trades at a trailing P/E of -35.44 on trailing EPS of -0.1590958569576041 TWD.
What do analysts rate 6932.TWO?
6932.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.